In pancreatic cancer, ANGPTL4 overexpression has been associated with tumorigenesis [19], cellular resistance to chemotherapy [8], hypoxia response, and poor patient outcomes [20]. This evidence concerns the gene ANGPTL4 and familial pancreatic carcinoma.